Hot Features
Premium
Register for streaming realtime charts, analysis tools, and prices.
The share price of Tissue Regenix Group plc (LSE:TRX) ignited and launched upward by 20% today to 20.85. There is no question about the reason why. The company has just signed seven independent sales agreements for representation in the U.S. Forty different sales representatives will present TRX’s proprietary dCELL® technology-based products to surgeons and hospitals in a band of northern states, stretching from Alaska to Maine. The sales agreements set the company on course to the eventual commercialization of of its DermaPure™ throughout the entire U.S. before the end of 2014.
The proprietary dCELL® technology is the platform upon which TRX intends to develop as many as 30 different tissue-engineered products for wound treatment in what the company calls “one of the most rapidly growing sectors within the medical products market.” The dCELL® process decellularizes harvested human and animal tissue to create a like-for-like tissue replacement for vascular, cardiac, and orthopedic applications in humans. The process allows surgeons to replace deteriorated or diseased human tissue with a similar animal tissue that the human body does not reject and which it literally incorporates and recellularizes as its own. Aside from the fact that surgeons need no different instruments or procedures to implant or apply DermaPure™, one obvious benefit for the patient, physically and financially, is that he or she requires no anti-rejection drugs.
In what may well become known as one of the greatest bio-technical advances in human history, TRX’s products, which, by the way, are already clinically proven, provide an immediately functioning, acellular, immuno-compatible therapeutic solution for a variety of issues from torn meniscus to deteriorated heart valves. Remarkably, the products can be stored at room temperature, yet another boon to the critical care facilities where they will be used.
On the financial side of the coin, holding 29.45% of the shares in issue, Invesco Ltd., is the major shareholder. Three months ago today, the TRX share price was 9.88. With today’s increase in share price, the company is valued at £137 million with 625.83 million shares in issue. Of £24.91 million in assets, £24.23 million is in working capital. The company already has an agreement in place with Community Tissue Services to tap the 6.5 million patient market in the U.S., a market currently estimated $1.4 billion. Panmure Gordon identified dCELL® correctly as “Disruptive technology, taking the incumbents head on.“
T-Rex once dominated the world. TRX is about to take its place.
